Eric Rowinsky

Eric Rowinsky is a prominent figure in the field of oncology, currently serving as a Strategic and Medical Consultant at Wuxi Biocity since April 2023. Rowinsky holds the position of President, Board of Directors, and Head of the Clinical Advisory Board at Rgenix since June 2015 and has been an Adjunct Professor of Medicine at New York University School of Medicine since April 2008. With a solid background in cancer therapeutic development, Rowinsky has provided expertise as a consultant for Oncodrugs since 1996. Previous roles include Chief Medical Officer at Hummingbird Bioscience and Stemline Therapeutics, and Executive Vice President and Chief Medical Officer at ImClone Systems. Rowinsky has held leadership positions in academic and clinical research, including a professorship at the University of Texas Health Science Center and directorship at the Institute for Drug Development. Education includes an MD from Vanderbilt University, a residency in Internal Medicine at UC San Diego, and a fellowship in Medical Oncology at The Johns Hopkins University, alongside a BA in Liberal Arts from New York University.